Predictive biomarkers, such as ER and HER2, help to categorize breast cancers as ER positive, HER2 positive, or triple negative (not expressing either of the two receptors or the progesterone receptor) and also serve as predictive biomarkers for the respective targeted therapies. The gene discussed is ESR1; the disease is breast carcinoma.